EuroBiotech Report—Nanobiotix soars, Novo backs NDE, Boehringer expansion, Summit and EMA-Amicus

(CC0 Public Domain)

Welcome to the latest edition of our weekly EuroBiotech Report. We start this week with Nanobiotix, which saw its stock soar after reporting phase 2/3 soft tissue sarcoma data. Novo Holdings invested CHF 20 million ($20 million) in NBE Therapeutics. Boehringer Ingelheim unveiled a €230 million investment in a German biologics center. Summit Therapeutics dumped its Duchenne muscular dystrophy drug following a midphase failure. The EMA told Amicus Therapeutics to generate more data before filing for conditional approval. And more.Nick Taylor  

1. Nanobiotix soars as late-phase cancer trial hits endpoint

A phase 2/3 trial of Nanobiotix’s NBTXR3 in soft tissue sarcoma has met (PDF) its primary endpoint. The top-line success against the pathological complete response rate endpoint sent Nanobiotix’s stock up by more than 50%.


Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

2. ADC startup NBE raises $20M from Novo Holdings, doubling size of Boehringer-backed B round

Novo Holdings has invested CHF 20 million ($20 million) in NBE Therapeutics, doubling the size of the startup’s series B round. NBE will use the money to start testing anti-ROR1 antibody-drug conjugate (ADC) NBE-002 in solid tumor patients.

3. Boehringer commits €230M to build German biologics center

Boehringer Ingelheim has unveiled a €230 million ($268 million) investment in its biologics capacity. The investment will support the construction of a biologics development center at Boehringer's R&D site in Biberach, Germany.

4. Summit dumps ezutromid after phase 2 Duchenne fail

Despite putting up encouraging early data, Summit Therapeutics' Duchenne muscular dystrophy (DMD) drug missed its primary and secondary endpoints in a phase 2 trial, leading the biotech to drop the program and focus its energies behind its antibiotic pipeline. 

5. EMA demands more data from Amicus, denting stock

The EMA has told Amicus Therapeutics it lacks the data to file for conditional approval of its Pompe disease drug in Europe. Amicus needs to gather data on more patients and track the progress of previously treated people before seeking conditional approval, delaying the filing to 2019 or beyond.

And more articles of note>>

Suggested Articles

Oncology is clearly a major medical and societal issue, but one that sees too much focus from biopharmas at the expense of other killers.

Durect’s share price fell 12% after half of the panel of painkiller experts recommended against approving Posimir.

China-based cancer and autoimmune disease biotech I-Mab Biopharma has raised $104 million on the U.S. Nasdaq composite.